LifeVantage Corp (LFVN) - Fiscal Year 2025 10-K Summary
Business Context and Reporting Period
Company: LifeVantage Corporation
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2025
Business Model: Direct selling of nutrigenomic dietary supplements, personal care products, and nootropics through a network of independent consultants. Key brands include Protandim, LifeVantage, TrueScience, and AXIO.
Geographic Reach: Operations in the Americas, Asia/Pacific, and Europe. Notably, the company ceased operations in the Philippines on June 30, 2025.
Key Financial Metrics
| Metric | FY 2025 | FY 2024 | Change |
|---|---|---|---|
| Net Revenue | $228.5 million | $200.2 million | +14.2% |
| Gross Profit | $183.7 million | $158.7 million | +15.8% |
| Gross Margin | 80.4% | 79.3% | +110 bps |
| Operating Income | $12.2 million | $4.3 million | +183.7% |
| Net Income | $9.8 million | $2.9 million | +236.9% |
| Diluted EPS | $0.75 | $0.23 | +226.1% |
| Cash & Equivalents | $20.2 million | $16.9 million | +19.5% |
| Operating Cash Flow | $11.9 million | $12.2 million | -2.5% |
| Debt (2024 Credit Facility) | $0 outstanding | $0 outstanding | — |
Material Changes vs. Prior Period
- Revenue Growth Drivers: Revenue increased primarily due to the launch of the MindBody GLP-1 System, which generated $40.8 million in revenue. This offset declines in the Protandim line (-$8.8 million) and TrueScience Liquid Collagen (-$4.7 million).
- Geographic Performance:
- Americas: Revenue grew 21.5% to $185.7 million, driven by the U.S. market (+22.5%) and the GLP-1 launch.
- Asia/Pacific & Europe: Revenue declined 9.4% to $42.8 million. Japan revenue fell 5.9%, and Australia/New Zealand fell 19.0%. The closure of the Philippines market contributed to the decline.
- Expense Management: Selling, General, and Administrative (SG&A) expenses decreased as a percentage of revenue (30.3% vs. 34.2%) due to the termination of the Real Salt Lake sponsorship and reduced proxy contest-related expenses. Commissions and incentives increased to 44.7% of revenue due to higher qualification rates in incentive programs.
- Account Growth: Total active accounts (consultants and customers) increased 3.1% to 132,000. Active independent consultants rose 4.1% to 51,000.
Guidance, Outlook, and Risks
Outlook & Strategy:
- Management plans to focus on increasing the average account base and enrollment of new consultants in FY 2026.
- Continued investment in the "Red Carpet" program to attract experienced sales leaders.
- Expansion of the MindBody GLP-1 System internationally.
- Capital allocation strategy remains balanced between reinvestment, quarterly dividends ($0.165/share in FY25), and share repurchases ($17.3 million remaining under the $60M program).
- Product Concentration: Protandim, LifeVantage, and TrueScience lines represent 87.6% of total revenue.
- Patent Expiration: U.S. patents for Protandim Nrf2 Synergizer expired in March 2025, potentially increasing competition.
- Regulatory Environment: Subject to strict FDA/FTC regulations regarding dietary supplement claims and direct selling practices. Risks include product recalls and independent consultant non-compliance.
- Supply Chain: Reliance on third-party manufacturers and suppliers for raw materials.
- Foreign Exchange: Significant revenue exposure to the Japanese Yen; a strengthening U.S. dollar negatively impacts reported revenue.
- Subsequent Event: On September 3, 2025, the company entered an agreement to acquire assets of LoveBiome (Global Organics Merchants, LLC), expected to close in mid-October 2025.
Investor Verification Checklist
- GLP-1 Sustainability: Verify if the $40.8M revenue from the new MindBody GLP-1 System is sustainable or if it cannibalized existing product sales.
- Patent Impact: Assess the competitive landscape post-March 2025 expiration of Protandim Nrf2 Synergizer patents.
- International Turnaround: Monitor the trajectory of the Asia/Pacific region, specifically the decline in Australia/New Zealand and the impact of the Philippines closure.
- Consultant Retention: Review churn rates for independent consultants, as revenue is heavily dependent on this network's stability.
- LoveBiome Acquisition: Evaluate the strategic fit and financial terms of the pending LoveBiome acquisition announced in September 2025.